Athersys (Athersys) Change In Working Capital : $1.81 Mil (TTM As of Sep. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Athersys Change In Working Capital?

Athersys's change in working capital for the quarter that ended in Sep. 2023 was $0.46 Mil.

Athersys's change in working capital for the fiscal year that ended in Dec. 2022 was $2.95 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Athersys Change In Working Capital Historical Data

The historical data trend for Athersys's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Athersys Change In Working Capital Chart

Athersys Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Change In Working Capital

Get a 7-Day Free Trial

5.45

3.71

8.69

0.55

2.95

Athersys Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Change In Working Capital	Get a 7-Day Free Trial															2.40	0.45	0.46	0.45	0.46

Athersys Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.81 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Athersys Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Athersys's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Athersys (Athersys) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Athersys Inc (OTCPK:ATHXQ) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

3201 Carnegie Avenue, Cleveland, OH, USA, 44115-2634

Website

https://www.athersys.com

Athersys Inc is a biotechnology company engaged in the field of regenerative medicine. It consists of research, clinical development, manufacturing, and manufacturing process development activities. The firm's main product is Multistem cell therapy. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and certain pulmonary conditions. Its revenue has been derived from corporate collaborations, license agreements, and government grants.

Executives

Neema Mayhugh	director	3201 CARNEGIE AVE, CLEVELAND OH 44115
Joseph Patrick Nolan	director	100 PARK LANE, LAKE BLUFF IL 60044
Daniel A. Camardo	director, officer: Chief Executive Officer	ATHERSYS, INC., 3201 CARNEGIE AVE, CLEVELAND OH 44115
Maia Hansen	officer: Chief Operating Officer	16430 N. SCOTTSDALE ROAD, SCOTTSDALE AZ 85254
Kasey Rosado	officer: Interim, CFO	485 LEXINGTON AVE 10TH FLOOR, NEW YORK NY 10017
Ismail Kola	director	3201 CARNEGIE AVENUE, CLEVELAND OH 44115
Ivor Macleod	officer: Chief Financial Officer	3201 CARNEGIE AVENUE, CLEVELAND OH 44115-2634
William Jr Lehmann	officer: President	3201 CARNEGIE AVENUE, CLEVELAND OH 44115
John J Harrington	director, officer: Chief Scientific Officer	3201 CARNEGIE AVENUE, CLEVELAND OH 44115
Laura K Campbell	officer: Vice President	3201 CARNEGIE AVENUE, CLEVELAND OH 44115
Katherine Bach Kalin	director	3201 CARNEGIE AVENUE, CLEVELAND OH 44115
Baiju R. Shah	director	ONE INVACARE WAY, ELYRIA OH 44035
Jane Wasman	director	C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Kenneth H Traub	director
Tadahisa Kagimoto	director, 10 percent owner	HEALIOS K.K., WORLD TRADE CENTER BLDG., 15F, 2-4-1 HAMAMATSUCHO, MINATO-KU, TOKYO M0 1056115